Deakin University
Browse

File(s) under permanent embargo

Taking a Breather: Advances in Interleukin 5 Inhibition for Asthma Relief

Version 2 2024-06-16, 00:15
Version 1 2022-11-24, 03:07
journal contribution
posted on 2022-11-24, 03:07 authored by Oliver MasseyOliver Massey, Cenk SuphiogluCenk Suphioglu
Interleukin 5 (IL-5) is a major cytokine responsible for eosinophil proliferation, migration and degranulation. Eosinophils play a considerable role in the manifestation of type 2 asthma, and therefore this makes IL-5 a unique and clinically important target for therapeutic intervention. Due to the critical role that IL-5 plays in all areas of eosinophil activity, it has been identified and targeted by three therapeutics, Mepolizumab, Benralizumab and Reslizumab. This review describes the IL-5 pathway and presents the clinical trial history of the three IL-5 inhibitors, to provide insight into the role of IL-5 in clinical asthma presentation. Additionally, this review aims to foster further investigation into the IL-5 pathway by describing current novel therapeutic discovery strategies with monoclonal antibodies.

History

Journal

International Journal of Molecular Sciences

Volume

23

Article number

11166

Pagination

1-13

Location

Basel, Switzerland

ISSN

1661-6596

eISSN

1422-0067

Language

English

Publication classification

C1 Refereed article in a scholarly journal

Issue

19

Publisher

MDPI